RA101495-02.202: A Phase 2 Study of Zilucoplan in Patients with Immune-Mediated Necrotizing Myopathy

Do you have immune-mediated necrotizing myopathy (IMNM)?

RA101495-02.202: A Phase 2 Study of Zilucoplan in Patients with Immune-Mediated Necrotizing Myopathy

Ra Pharma is developing an investigational drug, zilucoplan, for the treatment of patients with IMNM. Zilucoplan is designed to prevent the body’s immune attack on muscle cells by blocking a component of the body’s immune system called the complement pathway.

Watch the recorded version of the webinar,  “Introduction to Ra Pharma & the Potential of Zilucoplan for the Treatment of IMNM” to learn more.

The purpose of this study is to test the safety, tolerability, and effectiveness of zilucoplan for the treatment of patients with IMNM.

This study is a placebo-controlled study with an 8-week study treatment period. Study participants can continue their standard of care treatment during the study and will receive study drug as a self-administered (at home) subcutaneous injection once daily.

Your participation in this study would last approximately 12 weeks and would include approximately 7 study visits. You will have an option to receive active zilucoplan (not placebo) in a long-term extension study after completing this clinical trial.

To participate in this study, you will need to meet the following main entry criteria:

  1.  ≥18 years and <75 years of age
  2. Clinical diagnosis of IMNM
  3. Presence of antibodies for anti-HMGCR or anti-SRP
  4. Creatine Kinase > 1000

*Other inclusion or exclusion criteria may apply.

Learn more about the clinical trial here.

If you’re interested in participating in this trial please contact: trials@rapharma.com

Download the Ra Pharma study flyer here to save or print. 



Myositis Support and Understanding Association (MSU) is a patient-centered, all-volunteer 501(c)(3) nonprofit organization Empowering the Myositis Community. Founded by Myositis patients, for Myositis patients, MSU provides education, support, advocacy, access to research and clinical trial matching, and need-based financial assistance.

View more information: Myositis Support


Leave a reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2024 Myositis Support and Understanding Association (MSU). All rights reserved. | View our Privacy Policy, Terms, and Non-Discrimination policy. MSU is a charitable organization with 501(c)(3) tax-exempt status. Federal ID #47-4570748.

View COVID-19 resources and updates, and stay tuned to your state, local, and federal health agencies, along with the CDC.

Log in with your credentials


Forgot your details?

Register for Free Membership

Send this to a friend